Stay updated on BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial

Sign up to get notified when there's something new on the BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or important information.
    Difference
    0.2%
    Check dated 2025-09-07T13:36:28.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    The web page has undergone significant changes, including the addition of a facility name and specific location details in Beijing, while several related terms and categories have been removed, including various medical classifications and the previous version number.
    Difference
    3%
    Check dated 2025-08-31T11:33:38.000Z thumbnail image
  3. Check
    20 days ago
    No Change Detected
  4. Check
    28 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.11 to version 2.16.12, indicating a revision in the content.
    Difference
    0.1%
    Check dated 2025-08-17T01:36:10.000Z thumbnail image
  5. Check
    35 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.10 to version 2.16.11.
    Difference
    0.1%
    Check dated 2025-08-09T23:55:26.000Z thumbnail image
  6. Check
    42 days ago
    Change Detected
    Summary
    The web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.
    Difference
    1%
    Check dated 2025-08-02T18:18:36.000Z thumbnail image
  7. Check
    49 days ago
    Change Detected
    Summary
    The page has been updated to reflect a new version, changing from Revision v2.16.6 to v2.16.8, and includes the addition of HHS Vulnerability Disclosure.
    Difference
    0.2%
    Check dated 2025-07-26T14:25:54.000Z thumbnail image

Stay in the know with updates to BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial

Enter your email address, and we'll notify you when there's something new on the BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial page.